FATE

Fate Therapeutics, Inc.

Halal Rating :
Comfortable
Last Price $1.59 Last updated:
Market Cap $417.93m
7D Change -15.43%
1 Year Change -57.26%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange NASDAQ
Next Earnings Date Nov. 14, 2024

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company's proprietary induced pluripotent stem cell (iPSC) product platform enables the creation of off-the-shelf cellular immunotherapies. Their primary focus is on developing novel cellular immunotherapies for cancer and immune disorders using their proprietary iPSC product platform.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $3.07m $55.45m - - 0.00% 0.00%
June 30, 2024 $6.77m $51.85m - - 0.00% 0.00%
March 31, 2024 $1.93m $52.99m - - 0.00% 0.00%

Company Impact

Help us evaluate Fate Therapeutics, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates